T Cell Nouveau

T Cell Nouveau is a pre-clinical stage biotechnology company focused on developing a programmable "universal" CAR-T cell platform. Founded by Dr. Philip Low of Purdue University, the company's technology utilizes a single engineered T cell that remains inactive until a specific "adapter" molecule is administered. This system allows for precise control over T cell activity, the ability to target multiple antigens sequentially or simultaneously, and improved safety profiles compared to traditional CAR-T therapies. By decoupling the T cell from the target-binding domain, the platform aims to reduce toxicity and prevent antigen escape. The company's pipeline focuses on hematologic malignancies and expanding the reach of cell therapy into solid tumors.